Quark Pharmaceuticals

** QUARK is conducting A Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection of I5NP (AKIi-5) in Patients Undergoing Major Cardiovascular Surgery. This study is currently recruiting participants: clinicaltrials.gov

Quark Pharmaceuticals is an evolving pharmaceutical company using rational drug design to develop new therapeutics for unmet medical needs. Our proprietary te...

Modified siRNA in development for neovascular (wet) age-related macular degeneration (AMD), recently licensed to Pfizer. RTP801i-14 is a siRNA drug de...

Modified siRNA in development for acute renal failure (ARF). It inhibits the development of ARF in animals following a single iv injection. AKIi-5 wi...

10/13/2008

Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

Quark siRNAs Examined Alone and in Combination with Chemotherapy

9/25/2008

Quark Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property

Data Validates Neuroprotective Effect of Quark’s New RNAi product on dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma